Orexigen Therapeutics Inc.'s (Nasdaq: OREX) obesity treatment Contrave reduced the risk of heart disease by almost half. The stock price leaped $2.79 to $8.58.
Orexigen's Contrave lowers heart disease risk
March 03, 2015 at 12:33 PM EST
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.